Joint Formulary & PAD

Dienogest with estradiol valerate - Menstrual disorders and hormone-related gynaecological condition

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

Not recommended for new initiations. Existing patients may remain on this brand.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Dienogest with estradiol valerate
Indication :
Menstrual disorders and hormone-related gynaecological conditions
Group Name :
Keywords :
combined hormonal contraceptives, CHC, uterine fibroids, endometriosis, menorrhagia, heavy menstrual bleeding, dysmenorrhoea, menopausal symptoms, perimenopause symptoms, hot flushes, irregular periods, night sweats
Brand Names Include :
Qlaira
Important Information :

Combined hormonal contraceptives - used for a variety of disorders including uterine fibroids, menopausal symptoms, endometriosis, dysmenorrhoea, menorrhagia. Off-label use for some indications - see SPC

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Dienogest with estradiol valerate is used to treat.